NCT02695420 - Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2016

Primary Completion Date

April 6, 2017

Study Completion Date

May 8, 2017

Conditions

Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

25 mg Omecamtiv Mecarbil

oral tablet

DRUG

Placebo

oral tablet

DRUG

37.5 mg Omecamtiv Mecarbil

oral tablet

DRUG

50 mg Omecamtiv Mecarbil

oral tablet

Trial Locations (32)

486-8510

Research Site, Kasugai-shi

487-0016

Research Site, Kasugai-shi

454-8509

Research Site, Nagoya

289-2511

Research Site, Asahi-shi

260-8606

Research Site, Chiba

799-1592

Research Site, Imabari

818-8516

Research Site, Chikushino-shi

814-0180

Research Site, Fukuoka

815-8588

Research Site, Fukuoka

041-8512

Research Site, Hakodate-shi

060-8648

Research Site, Sapporo

660-8550

Research Site, Amagasaki-shi

666-0125

Research Site, Kawanishi-shi

665-0873

Research Site, Takarazuka-shi

920-8650

Research Site, Kanazawa

783-8505

Research Site, Nankoku-shi

870-0192

Research Site, Ōita

702-8055

Research Site, Okayama

596-8522

Research Site, Kishiwada-shi

532-0003

Research Site, Osaka

550-0012

Research Site, Osaka

559-0012

Research Site, Osaka

565-0871

Research Site, Suita-shi

840-8571

Research Site, Saga

330-8503

Research Site, Saitama-shi

351-0102

Research Site, Wako-shi

411-8611

Research Site, Sunto-gun

101-8309

Research Site, Chiyoda-ku

173-0015

Research Site, Itabashi-ku

173-8610

Research Site, Itabashi-ku

152-8902

Research Site, Meguro-ku

141-0001

Research Site, Shinagawa-ku